BMO Capital Markets Increases Sage Therapeutics, Inc. (SAGE) Price Target to $84.00

Sage Therapeutics, Inc. (NASDAQ:SAGE) had its price objective boosted by equities researchers at BMO Capital Markets from $80.00 to $84.00 in a note issued to investors on Thursday. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price points to a potential upside of 34.70% from the stock’s current price.

SAGE has been the subject of several other reports. BidaskClub lowered shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. J P Morgan Chase & Co dropped their target price on shares of Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating for the company in a research report on Tuesday. Chardan Capital reiterated a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday. ValuEngine upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Cowen and Company reissued a “buy” rating and set a $100.00 price target on shares of Sage Therapeutics in a research note on Friday, August 4th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $86.77.

Sage Therapeutics (SAGE) opened at 62.36 on Thursday. Sage Therapeutics has a 12 month low of $38.30 and a 12 month high of $90.80. The firm has a 50-day moving average of $81.33 and a 200 day moving average of $74.82. The firm’s market capitalization is $2.33 billion.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.25). During the same quarter last year, the company posted ($1.08) EPS. Equities research analysts forecast that Sage Therapeutics will post ($7.38) earnings per share for the current year.

WARNING: This story was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/16/bmo-capital-markets-increases-sage-therapeutics-inc-sage-price-target-to-84-00.html.

Several hedge funds and other institutional investors have recently modified their holdings of SAGE. Teachers Advisors LLC increased its stake in shares of Sage Therapeutics by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 49,296 shares of the biopharmaceutical company’s stock worth $2,517,000 after buying an additional 6,419 shares during the period. Bank of Montreal Can increased its stake in shares of Sage Therapeutics by 7,004.1% in the first quarter. Bank of Montreal Can now owns 12,006 shares of the biopharmaceutical company’s stock worth $853,000 after buying an additional 11,837 shares during the period. Janney Montgomery Scott LLC purchased a new position in shares of Sage Therapeutics in the first quarter worth $256,000. Russell Investments Group Ltd. increased its stake in shares of Sage Therapeutics by 82.1% in the first quarter. Russell Investments Group Ltd. now owns 19,679 shares of the biopharmaceutical company’s stock worth $1,399,000 after buying an additional 8,872 shares during the period. Finally, Swiss National Bank increased its stake in shares of Sage Therapeutics by 3.2% in the first quarter. Swiss National Bank now owns 52,100 shares of the biopharmaceutical company’s stock worth $3,703,000 after buying an additional 1,600 shares during the period.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply